Trial Profile

Clinical trial assessing ZGGS34 for the treatment of advanced solid tumors

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 11 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZGGS 34 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

11 Nov 2025 New trial record
17 Sep 2025 According to Suzhou Zelgen Biopharmaceuticals media release, company recently received approval from the National Medical Products Administration (NMPA) for its clinical trial of ZGGS34 for injection in the treatment of MUC17-positive advanced solid tumors.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com